- Home
- OP vs SILO Comparison
OP vs SILO Comparison
Compare OP & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- SILO
- Stock Information
- Founded
- OP 2021
- SILO 2010
- Country
- OP Greece
- SILO United States
- Employees
- OP N/A
- SILO N/A
- Industry
- OP
- SILO Apparel
- Sector
- OP
- SILO Consumer Discretionary
- Exchange
- OP Nasdaq
- SILO Nasdaq
- Market Cap
- OP 9.5M
- SILO 4.5M
- IPO Year
- OP N/A
- SILO N/A
- Fundamental
- Price
- OP $1.51
- SILO $0.57
- Analyst Decision
- OP
- SILO
- Analyst Count
- OP 0
- SILO 0
- Target Price
- OP N/A
- SILO N/A
- AVG Volume (30 Days)
- OP 8.8M
- SILO 312.4K
- Earning Date
- OP 08-06-2025
- SILO 08-12-2025
- Dividend Yield
- OP N/A
- SILO N/A
- EPS Growth
- OP N/A
- SILO N/A
- EPS
- OP N/A
- SILO N/A
- Revenue
- OP $25,702,000.00
- SILO $72,102.00
- Revenue This Year
- OP N/A
- SILO $1.86
- Revenue Next Year
- OP N/A
- SILO N/A
- P/E Ratio
- OP N/A
- SILO N/A
- Revenue Growth
- OP 35.58
- SILO N/A
- 52 Week Low
- OP $0.63
- SILO $0.41
- 52 Week High
- OP $3.17
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- OP 53.44
- SILO 45.29
- Support Level
- OP $1.16
- SILO $0.55
- Resistance Level
- OP $2.38
- SILO $0.69
- Average True Range (ATR)
- OP 0.22
- SILO 0.04
- MACD
- OP -0.04
- SILO 0.00
- Stochastic Oscillator
- OP 40.57
- SILO 28.57
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.